Disc Medicine (IRON) reported a 2024 loss Thursday of $3.96 per share, wider than a loss of $3.42 a year earlier.
Analysts polled by FactSet expected a loss of $4.13.
As expected, no revenue was reported.
As of Dec. 31, the company had $489.9 million in cash, cash equivalents and marketable securities. Combined with $243.3 million from an underwritten public offering, the company said it expects this will fund its operations into 2028.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。